Intriguingly, when classifying breast cancer patients according to their sensitivity to chemotherapy, we found that plasma ACE2 levels were significantly higher in chemotherapy-insensitive patients than in sensitive patients (Fig. 2E; Table 1, P < 0.0001). Here, ACE2 is linked to breast cancer.